Jeffrey G. Spragens - 15 Jul 2024 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Director
Signature
/s/ Jeffrey G. Spragens
Issuer symbol
SABS
Transactions as of
15 Jul 2024
Net transactions value
$0
Form type
4
Filing time
17 Jul 2024, 16:30:14 UTC
Previous filing
02 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Stock Option (right to buy) Award $0 +20,000 $0.000000 20,000 15 Jul 2024 Common Stock 20,000 $2.90 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.
F2 This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.